MP
RLMD icon

Mangrove Partners’s Relmada Therapeutics RLMD Stock Holding History

Mangrove Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$499K Buy
71,705
+44,325
+162% +$210K 0.04% 200
2025
Q4 		$132K Buy
+27,380
New +$91.7K 0.01% 343
2022
Q2 		– Sell
-258,094
Closed -$6.97M – 530
2022
Q1 		$6.97M Buy
258,094
+125,000
+94% +$2.58M 0.38% 50
2021
Q4 		$3M Sell
133,094
-26,074
-16% -$580K 0.18% 184
2021
Q3 		$4.17M Buy
159,168
+112,192
+239% +$3M 0.37% 76
2021
Q2 		$1.5M Buy
+46,976
New +$1.63M 0.15% 208

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Mangrove Partners's RLMD Position: Q1 2026 in Review

Mangrove Partners increased its Relmada Therapeutics (RLMD) stake by 162% in Q1 2026, buying an estimated $210K and bringing the position to 71,705 shares worth $499K. The position accounts for 0.04% of the portfolio, ranked #200.

Mangrove Partners first reported a position in RLMD in Q2 2021 and has held it in 6 quarters since. The position peaked at $6.97M in Q1 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Mangrove Partners held 71,705 shares of Relmada Therapeutics worth $499K as of Q1 2026.
  • Mangrove Partners bought 44,325 Relmada Therapeutics shares in Q1 2026, an estimated $210K.
  • Relmada Therapeutics made up 0.04% of Mangrove Partners's portfolio in Q1 2026, its #200 holding.
  • Mangrove Partners first reported a position in Relmada Therapeutics in Q2 2021 and has held it in 6 quarters since.
  • Mangrove Partners's Relmada Therapeutics position peaked at $6.97M in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.